1Zhong N, Wang C, Yao W, et at. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med, 2007, 176 : 753-760.
4Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med, 1991, 85 Suppl B: 25- 31.
5Briggs A, Glick H, Lozano-Ortega G, et al. The TORCH (Towards a Revolution in COPD Health ) study: Salmeterol/Fluticasone propionate improves quality adjusted survival over three years. Thorax, 2006, 61 Suppl 2 : ii39.
6Jones PW. Spencer S, Adie S. The St. George's respiratory questionnaire manual. 2.1th ed. London: St. George's Hospital Medical School, 2003.
7Petty TL, Definition, epidemiology, course, and prognosis of COPD. Clin Cornerstone, 2003, 5 : 1-10.
8Fukuchi Y, Nishimura M, Ichinose M, et al. COPD in Japan: the Nippon COPD Epidemiology study. Respirology, 2004, 9: 458- 465
9National Heart, Lung and Blood Institute Organization [ M/OL]. Morbidity and mortality chartbook on cardiovascular, lung and diseases. Bethesda: National Heart,Lung, and Blood Institute, 2007 [ 2008-1-12 ]. http://www.nhlbi.nih. gov/resources/docs/ cht-book.htm
10Sin DD, Stafinski T, Ng YC, et al. The impact of chronic obstructive pulmonary disease on work loss in the United States. Am J Respir Crit Care Med, 2002, 165 : 704-707.
4Van Wetering CR, Hoogendoorn M, Mol SJ, et al. Short - and long - term efficacy of a community - based COPD management programme in less advanced COPD: A randomised controlled trial. [J]. Thorax, 2010,65(1):7 - 13.
